|
Bolt Biotherapeutics Inc (NASDAQ: BOLT) |
|
Bolt Biotherapeutics Inc
BOLT's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Bolt Biotherapeutics Inc 's sales fell
by -54.87 % in III. Quarter 2024 from the same quarter a year ago.
Ranking at No. 1154
Major Pharmaceutical Preparations industry recorded
growth of revenues by 9.75 %
Bolt Biotherapeutics Inc net loss decreased from $-16 millions, to $-15 millions in III. Quarter 2024,
• More on BOLT's Growth
|
|
Bolt Biotherapeutics Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 91.62 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 2.01.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.01.
• More on BOLT's Valuation
|
|
|
|
|
Bolt Biotherapeutics Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 91.62 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 2.01.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.01.
Bolt Biotherapeutics Inc Price to Book Ratio is at 0.27 lower than Industry Avg. of 77.58. and higher than S&P 500 Avg. of 0.01
• More on BOLT's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com